Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 354

1.

BCOR Expression in Mullerian Adenosarcoma: A Potential Diagnostic Pitfall.

Muthukumarana V, Fix DJ, Stolnicu S, Park KJ, Soslow RA, Benayed R, Ladanyi M, Antonescu CR, Chiang S.

Am J Surg Pathol. 2020 Jan 29. doi: 10.1097/PAS.0000000000001445. [Epub ahead of print]

PMID:
32011345
2.

Withdrawal: Microsomal prostaglandin E synthase-1 is overexpressed in inflammatory bowel disease: Evidence for involvement of the transcription factor Egr-1.

Subbaramaiah K, Yoshimatsu K, Scherl E, Das KM, Glazier KD, Golijanin D, Soslow RA, Tanabe T, Naraba H, Dannenberg AJ.

J Biol Chem. 2020 Jan 3;295(1):293. doi: 10.1074/jbc.W119.012138. No abstract available.

3.

Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary.

Kim SH, Da Cruz Paula A, Basili T, Dopeso H, Bi R, Pareja F, da Silva EM, Gularte-Mérida R, Sun Z, Fujisawa S, Smith CG, Ferrando L, Martins Sebastião AP, Bykov Y, Li A, Silveira C, Ashley CW, Stylianou A, Selenica P, Samore WR, Jungbluth AA, Zamarin D, Abu-Rustum NR, Helin K, Soslow RA, Reis-Filho JS, Oliva E, Weigelt B.

Nat Commun. 2020 Jan 2;11(1):44. doi: 10.1038/s41467-019-13806-x.

4.

Retained mismatch repair protein expression occurs in approximately 6% of microsatellite instability-high cancers and is associated with missense mutations in mismatch repair genes.

Hechtman JF, Rana S, Middha S, Stadler ZK, Latham A, Benayed R, Soslow R, Ladanyi M, Yaeger R, Zehir A, Shia J.

Mod Pathol. 2019 Dec 19. doi: 10.1038/s41379-019-0414-6. [Epub ahead of print]

PMID:
31857677
5.

Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas.

León-Castillo A, Gilvazquez E, Nout R, Smit VT, McAlpine JN, McConechy M, Kommoss S, Brucker SY, Carlson JW, Epstein E, Rau TT, Soslow RA, Ganesan R, Matias-Guiu X, Oliva E, Harrison BT, Church DN, Gilks CB, Bosse T.

J Pathol. 2019 Dec 12. doi: 10.1002/path.5373. [Epub ahead of print]

6.

Wilms Tumor of the Ovary: Review of the Literature and Report of 2 Cases.

Turashvili G, Fix DJ, Soslow RA, Park KJ.

Int J Gynecol Pathol. 2020 Jan;39(1):72-78. doi: 10.1097/PGP.0000000000000565.

PMID:
31815892
7.

Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.

Stasenko M, Tunnage I, Ashley CW, Rubinstein MM, Latham AJ, Da Cruz Paula A, Mueller JJ, Leitao MM Jr, Friedman CF, Makker V, Soslow RA, DeLair DF, Hyman DM, Zamarin D, Alektiar KM, Aghajanian CA, Abu-Rustum NR, Weigelt B, Cadoo KA.

Gynecol Oncol. 2020 Jan;156(1):194-202. doi: 10.1016/j.ygyno.2019.10.028. Epub 2019 Nov 19.

PMID:
31757464
8.

Sentinel lymph node mapping alone compared to more extensive lymphadenectomy in patients with uterine serous carcinoma.

Basaran D, Bruce S, Aviki EM, Mueller JJ, Broach VA, Cadoo K, Soslow RA, Alektiar KM, Abu-Rustum NR, Leitao MM Jr.

Gynecol Oncol. 2020 Jan;156(1):70-76. doi: 10.1016/j.ygyno.2019.10.005. Epub 2019 Nov 16.

PMID:
31739992
9.

Clinicopathologic Association and Prognostic Value of MELF Pattern in Invasive Endocervical Adenocarcinoma (ECA) as Classified by IECC.

Segura SE, Hoang L, Boros M, Terinte C, Pesci A, Aviel-Ronen S, Kiyokawa T, Alvarado-Cabrero I, Oliva E, Park KJ, Soslow RA, Stolnicu S.

Int J Gynecol Pathol. 2019 Sep 11. doi: 10.1097/PGP.0000000000000633. [Epub ahead of print]

PMID:
31517653
10.

Recent advances in invasive adenocarcinoma of the cervix.

Stolnicu S, Hoang L, Soslow RA.

Virchows Arch. 2019 Nov;475(5):537-549. doi: 10.1007/s00428-019-02601-0. Epub 2019 Jun 17. Review.

PMID:
31209635
11.

A descriptive report of outcomes of primary mucinous ovarian cancer patients receiving either an adjuvant gynecologic or gastrointestinal chemotherapy regimen.

Schlappe BA, Zhou QC, O'Cearbhaill R, Iasonos A, Soslow RA, Abu-Rustum NR, Mueller JJ.

Int J Gynecol Cancer. 2019 May 15. pii: ijgc-2018-000150. doi: 10.1136/ijgc-2018-000150. [Epub ahead of print]

PMID:
31097512
12.

Micropapillary Cervical Adenocarcinoma: A Clinicopathologic Study of 44 Cases.

Alvarado-Cabrero I, McCluggage WG, Estevez-Castro R, Pérez-Montiel D, Stolnicu S, Ganesan R, Vella J, Castro R, Canedo-Matute J, Gomez-Cifuentes J, Rivas-Lemus VM, Park KJ, Soslow RA, Oliva E, Valencia-Cedillo R.

Am J Surg Pathol. 2019 Jun;43(6):802-809. doi: 10.1097/PAS.0000000000001245.

PMID:
30864975
13.

PGR Gene Fusions Identify a Molecular Subset of Uterine Epithelioid Leiomyosarcoma With Rhabdoid Features.

Chiang S, Samore W, Zhang L, Sung YS, Turashvili G, Murali R, Soslow RA, Hensley ML, Swanson D, Dickson BC, Stewart CJR, Oliva E, Antonescu CR.

Am J Surg Pathol. 2019 Jun;43(6):810-818. doi: 10.1097/PAS.0000000000001239.

PMID:
30829727
14.

Undifferentiated Uterine Sarcomas Represent Under-Recognized High-grade Endometrial Stromal Sarcomas.

Cotzia P, Benayed R, Mullaney K, Oliva E, Felix A, Ferreira J, Soslow RA, Antonescu CR, Ladanyi M, Chiang S.

Am J Surg Pathol. 2019 May;43(5):662-669. doi: 10.1097/PAS.0000000000001215.

PMID:
30789359
15.

A pragmatic approach to carcinomas concurrently involving the endometrium and ovary.

Murali R, Soslow RA.

Gynecol Oncol Rep. 2018 Dec 30;27:74. doi: 10.1016/j.gore.2018.12.010. eCollection 2019 Feb. No abstract available.

16.

Clinical Outcomes of HPV-associated and Unassociated Endocervical Adenocarcinomas Categorized by the International Endocervical Adenocarcinoma Criteria and Classification (IECC).

Stolnicu S, Hoang L, Chiu D, Hanko-Bauer O, Terinte C, Pesci A, Aviel-Ronen S, Kiyokawa T, Alvarado-Cabrero I, Oliva E, Park KJ, Abu-Rustum NR, Soslow RA.

Am J Surg Pathol. 2019 Apr;43(4):466-474. doi: 10.1097/PAS.0000000000001224.

PMID:
30720532
17.

Somatic genetic alterations in synchronous and metachronous low-grade serous tumours and high-grade carcinomas of the adnexa.

Murali R, Selenica P, Brown DN, Cheetham RK, Chandramohan R, Claros NL, Bouvier N, Cheng DT, Soslow RA, Weigelt B, McCluggage WG.

Histopathology. 2019 Mar;74(4):638-650. doi: 10.1111/his.13796. Epub 2019 Jan 15.

PMID:
30565721
18.

Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists.

Soslow RA, Tornos C, Park KJ, Malpica A, Matias-Guiu X, Oliva E, Parkash V, Carlson J, McCluggage WG, Gilks CB.

Int J Gynecol Pathol. 2019 Jan;38 Suppl 1:S64-S74. doi: 10.1097/PGP.0000000000000518. Review.

19.

High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations.

Murali R, Davidson B, Fadare O, Carlson JA, Crum CP, Gilks CB, Irving JA, Malpica A, Matias-Guiu X, McCluggage WG, Mittal K, Oliva E, Parkash V, Rutgers JKL, Staats PN, Stewart CJR, Tornos C, Soslow RA.

Int J Gynecol Pathol. 2019 Jan;38 Suppl 1:S40-S63. doi: 10.1097/PGP.0000000000000491. Review.

20.

Wilms Tumor of the Ovary: Review of the Literature and Report of 2 Cases.

Turashvili G, Fix DJ, Soslow RA, Park KJ.

Int J Gynecol Pathol. 2018 Dec 3. doi: 10.1097/PGP.0000000000000565. [Epub ahead of print]

PMID:
30516617
21.

Novel PLAG1 Gene Rearrangement Distinguishes a Subset of Uterine Myxoid Leiomyosarcoma From Other Uterine Myxoid Mesenchymal Tumors.

Arias-Stella JA 3rd, Benayed R, Oliva E, Young RH, Hoang LN, Lee CH, Jungbluth AA, Frosina D, Soslow RA, Antonescu CR, Ladanyi M, Chiang S.

Am J Surg Pathol. 2019 Mar;43(3):382-388. doi: 10.1097/PAS.0000000000001196.

PMID:
30489320
22.

Association between CT-texture-derived tumor heterogeneity, outcomes, and BRCA mutation status in patients with high-grade serous ovarian cancer.

Meier A, Veeraraghavan H, Nougaret S, Lakhman Y, Sosa R, Soslow RA, Sutton EJ, Hricak H, Sala E, Vargas HA.

Abdom Radiol (NY). 2019 Jun;44(6):2040-2047. doi: 10.1007/s00261-018-1840-5.

PMID:
30474722
23.

Risk-based stratification of carcinomas concurrently involving the endometrium and ovary.

Turashvili G, Gómez-Hidalgo NR, Flynn J, Gonen M, Leitao MM Jr, Soslow RA, Murali R.

Gynecol Oncol. 2019 Jan;152(1):38-45. doi: 10.1016/j.ygyno.2018.10.033. Epub 2018 Nov 6.

24.

Patterns of FIRST recurrence of stage IIIC1 endometrial cancer with no PARAAORTIC nodal assessment.

Aloisi A, Casanova JM, Tseng JH, Seader KA, Nguyen NT, Alektiar KM, Makker V, Chiang S, Soslow RA, Leitao MM Jr, Abu-Rustum NR.

Gynecol Oncol. 2018 Dec;151(3):395-400. doi: 10.1016/j.ygyno.2018.09.021. Epub 2018 Oct 2.

25.

Cervical adenosquamous carcinoma: detailed analysis of morphology, immunohistochemical profile, and clinical outcomes in 59 cases.

Stolnicu S, Hoang L, Hanko-Bauer O, Barsan I, Terinte C, Pesci A, Aviel-Ronen S, Kiyokawa T, Alvarado-Cabrero I, Oliva E, Park KJ, Soslow RA.

Mod Pathol. 2019 Feb;32(2):269-279. doi: 10.1038/s41379-018-0123-6. Epub 2018 Sep 26.

26.

Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study.

Visvanathan K, Shaw P, May BJ, Bahadirli-Talbott A, Kaushiva A, Risch H, Narod S, Wang TL, Parkash V, Vang R, Levine DA, Soslow R, Kurman R, Shih IM.

Cancer Prev Res (Phila). 2018 Nov;11(11):697-706. doi: 10.1158/1940-6207.CAPR-18-0009. Epub 2018 Sep 19.

27.

Multicenter study comparing oncologic outcomes between two nodal assessment methods in patients with deeply invasive endometrioid endometrial carcinoma: A sentinel lymph node algorithm versus a comprehensive pelvic and paraaortic lymphadenectomy.

Schlappe BA, Weaver AL, Ducie JA, Eriksson AGZ, Dowdy SC, Cliby WA, Glaser GE, Soslow RA, Alektiar KM, Makker V, Abu-Rustum NR, Mariani A, Leitao MM Jr.

Gynecol Oncol. 2018 Nov;151(2):235-242. doi: 10.1016/j.ygyno.2018.08.022. Epub 2018 Aug 31.

28.

Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer.

Soumerai TE, Donoghue MTA, Bandlamudi C, Srinivasan P, Chang MT, Zamarin D, Cadoo KA, Grisham RN, O'Cearbhaill RE, Tew WP, Konner JA, Hensley ML, Makker V, Sabbatini P, Spriggs DR, Troso-Sandoval TA, Charen AS, Friedman C, Gorsky M, Schweber SJ, Middha S, Murali R, Chiang S, Park KJ, Soslow RA, Ladanyi M, Li BT, Mueller J, Weigelt B, Zehir A, Berger MF, Abu-Rustum NR, Aghajanian C, DeLair DF, Solit DB, Taylor BS, Hyman DM.

Clin Cancer Res. 2018 Dec 1;24(23):5939-5947. doi: 10.1158/1078-0432.CCR-18-0412. Epub 2018 Aug 1.

29.

Tubo-Ovarian Transitional Cell Carcinoma and High-grade Serous Carcinoma Show Subtly Different Immunohistochemistry Profiles.

Magrill J, Karnezis AN, Tessier-Cloutier B, Talhouk A, Kommoss S, Cochrane D, Chow C, Cheng A, Soslow R, Hauptmann S, du Bois A, Pfisterer J, Gilks CB, Huntsman DG, Kommoss F.

Int J Gynecol Pathol. 2019 Nov;38(6):552-561. doi: 10.1097/PGP.0000000000000538.

PMID:
30059451
30.

International Endocervical Adenocarcinoma Criteria and Classification: Validation and Interobserver Reproducibility.

Hodgson A, Park KJ, Djordjevic B, Howitt BE, Nucci MR, Oliva E, Stolnicu S, Xu B, Soslow RA, Parra-Herran C.

Am J Surg Pathol. 2019 Jan;43(1):75-83. doi: 10.1097/PAS.0000000000001095.

31.

Stromal invasion pattern identifies patients at lowest risk of lymph node metastasis in HPV-associated endocervical adenocarcinomas, but is irrelevant in adenocarcinomas unassociated with HPV.

Stolnicu S, Barsan I, Hoang L, Patel P, Terinte C, Pesci A, Aviel-Ronen S, Kiyokawa T, Alvarado-Cabrero I, Oliva E, Park KJ, Abu-Rustum NR, Pike MC, Soslow RA.

Gynecol Oncol. 2018 Jul;150(1):56-60. doi: 10.1016/j.ygyno.2018.04.570. Epub 2018 May 30.

32.

Diagnostic Algorithmic Proposal Based on Comprehensive Immunohistochemical Evaluation of 297 Invasive Endocervical Adenocarcinomas.

Stolnicu S, Barsan I, Hoang L, Patel P, Chiriboga L, Terinte C, Pesci A, Aviel-Ronen S, Kiyokawa T, Alvarado-Cabrero I, Pike MC, Oliva E, Park KJ, Soslow RA.

Am J Surg Pathol. 2018 Aug;42(8):989-1000. doi: 10.1097/PAS.0000000000001090.

33.

A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.

Aghajanian C, Filiaci V, Dizon DS, Carlson JW, Powell MA, Secord AA, Tewari KS, Bender DP, O'Malley DM, Stuckey A, Gao J, Dao F, Soslow RA, Lankes HA, Moore K, Levine DA.

Gynecol Oncol. 2018 Aug;150(2):274-281. doi: 10.1016/j.ygyno.2018.05.018. Epub 2018 May 24.

34.

Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses.

Mueller JJ, Schlappe BA, Kumar R, Olvera N, Dao F, Abu-Rustum N, Aghajanian C, DeLair D, Hussein YR, Soslow RA, Levine DA, Weigelt B.

Gynecol Oncol. 2018 Jul;150(1):127-135. doi: 10.1016/j.ygyno.2018.05.008. Epub 2018 May 22.

35.

BRAFV600E mutations and immunohistochemical expression of VE1 protein in low-grade serous neoplasms of the ovary.

Turashvili G, Grisham RN, Chiang S, DeLair DF, Park KJ, Soslow RA, Murali R.

Histopathology. 2018 Sep;73(3):438-443. doi: 10.1111/his.13651. Epub 2018 Jun 22.

36.

Morphologic Features of Gastric-type Cervical Adenocarcinoma in Small Surgical and Cytology Specimens.

Turashvili G, Morency EG, Kracun M, DeLair DF, Chiang S, Soslow RA, Park KJ, Murali R.

Int J Gynecol Pathol. 2019 May;38(3):263-275. doi: 10.1097/PGP.0000000000000519.

PMID:
29750702
37.

Frequent loss of claudin-4 expression in dedifferentiated and undifferentiated endometrial carcinomas.

Tessier-Cloutier B, Soslow RA, Stewart CJR, Köbel M, Lee CH.

Histopathology. 2018 Aug;73(2):299-305. doi: 10.1111/his.13525. Epub 2018 May 31.

38.

International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers.

Mueller JJ, Lajer H, Mosgaard BJ, Bach Hamba S, Morice P, Gouy S, Hussein Y, Soslow RA, Schlappe BA, Zhou QC, Iasonos A, Høgdall C, Leary A, O'Cearbhaill RE, Abu-Rustum NR.

Int J Gynecol Cancer. 2018 Jun;28(5):915-924. doi: 10.1097/IGC.0000000000001263.

39.

NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma.

Chiang S, Cotzia P, Hyman DM, Drilon A, Tap WD, Zhang L, Hechtman JF, Frosina D, Jungbluth AA, Murali R, Park KJ, Soslow RA, Oliva E, Iafrate AJ, Benayed R, Ladanyi M, Antonescu CR.

Am J Surg Pathol. 2018 Jun;42(6):791-798. doi: 10.1097/PAS.0000000000001055.

40.

Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study.

Ring BZ, Murali R, Soslow RA, Bowtell DDL, Fereday S, deFazio A, Traficante N, Kennedy CJ, Brand A, Sharma R, Harnett P, Samimi G; Australian Ovarian Cancer Study.

Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):680-688. doi: 10.1158/1055-9965.EPI-17-1101. Epub 2018 Mar 12.

41.

Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility.

Köbel M, Ronnett BM, Singh N, Soslow RA, Gilks CB, McCluggage WG.

Int J Gynecol Pathol. 2019 Jan;38 Suppl 1:S123-S131. doi: 10.1097/PGP.0000000000000488. Review.

42.

Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.

Bosse T, Nout RA, McAlpine JN, McConechy MK, Britton H, Hussein YR, Gonzalez C, Ganesan R, Steele JC, Harrison BT, Oliva E, Vidal A, Matias-Guiu X, Abu-Rustum NR, Levine DA, Gilks CB, Soslow RA.

Am J Surg Pathol. 2018 May;42(5):561-568. doi: 10.1097/PAS.0000000000001020.

43.

CT Features of Ovarian Tumors: Defining Key Differences Between Serous Borderline Tumors and Low-Grade Serous Carcinomas.

Nougaret S, Lakhman Y, Molinari N, Feier D, Scelzo C, Vargas HA, Sosa RE, Hricak H, Soslow RA, Grisham RN, Sala E.

AJR Am J Roentgenol. 2018 Apr;210(4):918-926. doi: 10.2214/AJR.17.18254. Epub 2018 Feb 28.

44.

Evolving Roles of Histologic Evaluation and Molecular/Genomic Profiling in the Management of Endometrial Cancer.

Murali R, Delair DF, Bean SM, Abu-Rustum NR, Soslow RA.

J Natl Compr Canc Netw. 2018 Feb;16(2):201-209. doi: 10.6004/jnccn.2017.7066. Review.

45.

A guided tour of selected issues pertaining to metastatic carcinomas involving or originating from the gynecologic tract.

Soslow RA, Murali R.

Semin Diagn Pathol. 2018 Mar;35(2):95-107. doi: 10.1053/j.semdp.2017.11.007. Epub 2017 Nov 20. Review. No abstract available.

46.

Molecular insights into the classification of high-grade endometrial carcinoma.

Hussein YR, Soslow RA.

Pathology. 2018 Feb;50(2):151-161. doi: 10.1016/j.pathol.2017.09.010. Epub 2017 Dec 13. Review.

PMID:
29246451
47.

ZC3H7B-BCOR high-grade endometrial stromal sarcomas: a report of 17 cases of a newly defined entity.

Lewis N, Soslow RA, Delair DF, Park KJ, Murali R, Hollmann TJ, Davidson B, Micci F, Panagopoulos I, Hoang LN, Arias-Stella JA 3rd, Oliva E, Young RH, Hensley ML, Leitao MM Jr, Hameed M, Benayed R, Ladanyi M, Frosina D, Jungbluth AA, Antonescu CR, Chiang S.

Mod Pathol. 2018 Apr;31(4):674-684. doi: 10.1038/modpathol.2017.162. Epub 2017 Dec 1.

48.

The roles of pathology in targeted therapy of women with gynecologic cancers.

Murali R, Grisham RN, Soslow RA.

Gynecol Oncol. 2018 Jan;148(1):213-221. doi: 10.1016/j.ygyno.2017.11.020. Epub 2017 Nov 23. Review.

49.

International Endocervical Adenocarcinoma Criteria and Classification (IECC): A New Pathogenetic Classification for Invasive Adenocarcinomas of the Endocervix.

Stolnicu S, Barsan I, Hoang L, Patel P, Terinte C, Pesci A, Aviel-Ronen S, Kiyokawa T, Alvarado-Cabrero I, Pike MC, Oliva E, Park KJ, Soslow RA.

Am J Surg Pathol. 2018 Feb;42(2):214-226. doi: 10.1097/PAS.0000000000000986.

50.

Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma.

Ducie J, Dao F, Considine M, Olvera N, Shaw PA, Kurman RJ, Shih IM, Soslow RA, Cope L, Levine DA.

Nat Commun. 2017 Oct 17;8(1):990. doi: 10.1038/s41467-017-01217-9.

Supplemental Content

Loading ...
Support Center